NICE to look again at decision not to fund lecanemab and donanemab for NHS use
The National Institute for Health and Care Excellence (NICE) is to look again at its decision not to fund Alzheimer’s disease drugs lecanemab and donanemab for use on the NHS.
An appeal has found that NICE failed to properly account for the wider impact of the treatments, including on unpaid carers, when calculating the cost effectiveness of lecanemab and donanemab.
Lecanemab and donanemab will now return to a NICE committee for further consideration.
More about lecanemab on the NICE website here: https://www.nice.org.uk/guidance/indevelopment/gid-ta11220
More about donanemab on the NICE website here: https://www.nice.org.uk/guidance/indevelopment/gid-ta11221
Read Dementia Community’s coverage of lecanemab here: https://journalofdementiacare.co.uk/?s=lecanemab
Read Dementia Community’s coverage on donanemab here: https://journalofdementiacare.co.uk/?s=donanemab